Marta Bes

Dr. Marta Bes


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Emerging Infectious Diseases
Verified
Journal Article
Open access
MBMarta Bes
Marta Bes
MCMaria I. Costafreda
Maria I. Costafreda
MRMar Riveiro-Barciela
Mar Riveiro-Barciela
MPMaria Piron
Maria Piron
ARAngie Rico
Angie Rico
SSSilvia Sauleda
Silvia Sauleda
HEV RNA Universal Blood Donor Screening, Spain

Verified
Journal Article
Open access
PDF file
MLMeritxell Llorens-Revull
Meritxell Llorens-Revull
BMBrenda Martínez-González
Brenda Martínez-González
JQJosep Quer
Josep Quer
JEJuan Ignacio Esteban
Juan Ignacio Esteban
GNGonzalo Núñez-Moreno
Gonzalo Núñez-Moreno
Maria I. CostafredaMaria I. Costafreda
Maria I. Costafreda
MicroRNAs (miRNAs) encapsulated in extracellular vesicles (EVs) are potential diagnostic and prognostic biomarkers. However, discrepancies in miRNA patterns and their validation are still frequent due to differences in sample origin, EV isolation, and miRNA sequencing methods. The aim of the present study is to find a reliable EV isolation method for miRNA sequencing, adequate for clinical application. To this aim, two comparative studies were performed in parallel with the same human plasma sample: (i) isolation and characterization of EVs obtained using three procedures: size exclusion chromatography (SEC), iodixanol gradient (GRAD), and its combination (SEC+GRAD) and (ii) evaluation of the yield of miRNA sequences obtained using NextSeq 500 (Illumina) and three miRNA library preparation protocols: NEBNext, NEXTFlex, and SMARTer smRNA-seq. The conclusion of comparison (i) is that recovery of the largest amount of EVs and reproducibility were attained with SEC, but GRAD and SEC+GRAD yielded purer EV preparations. The conclusion of (ii) is that the NEBNext library showed the highest reproducibility in the number of miRNAs recovered and the highest diversity of miRNAs. These results render the combination of GRAD EV isolation and NEBNext library preparation for miRNA retrieval as adequate for clinical applications using plasma samples.

9 July 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMeritxell Llorens-Revull
Meritxell Llorens-Revull
MCMaria Isabel Costafreda
Maria Isabel Costafreda
ARAngie Rico
Angie Rico
MGMercedes Guerrero-Murillo
Mercedes Guerrero-Murillo
MSMaria Eugenia Soria
Maria Eugenia Soria
MBMarta Bes
Marta Bes
Background & aims: HCV CD4+ and CD8+ specific T cells responses are functionally impaired during chronic hepatitis C infection. DAAs therapies eradicate HCV infection in more than 95% of treated patients. However, the impact of HCV elimination on immune responses remain controversial. Here, we aimed to investigate whether HCV cure by DAAs could reverse the impaired immune response to HCV. Methods: We analyzed 27 chronic HCV infected patients undergoing DAA treatment in tertiary care hospital, and we determined the phenotypical and functional changes in both HCV CD8+ and CD4+ specific T-cells before and after viral clearance. PD-1, TIM-3 and LAG-3 cell-surface expression was assessed by flow cytometry to determine CD4+ T cell exhaustion. Functional responses to HCV were analyzed by IFN-Ɣ ELISPOT, intracellular cytokine staining (IL-2 and IFN-Ɣ) and CFSE-based proliferation assays. Results: We observed a significant decrease in the expression of PD-1 in CD4+ T-cells after 12 weeks of viral clearance in non-cirrhotic patients (p = 0.033) and in treatment-naive patients (p = 0.010), indicating a partial CD4 phenotype restoration. IFN-Ɣ and IL-2 cytokines production by HCV-specific CD4+ and CD8+ T cells remained impaired upon HCV eradication. Finally, a significant increase of the proliferation capacity of both HCV CD4+ and CD8+ specific T-cells was observed after HCV elimination by DAAs therapies. Conclusions: Our results show that in chronically infected patients HCV elimination by DAA treatment lead to partial reversion of CD4+ T cell exhaustion. Moreover, proliferative capacity of HCV-specific CD4+ and CD8+ T cells is recovered after DAA’s therapies.

24 April 2022 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
LRLuisa Roade
Luisa Roade
MRMar Riveiro-Barciela
Mar Riveiro-Barciela
APAdriana Palom
Adriana Palom
FRFrancisco Rodríguez-Frías
Francisco Rodríguez-Frías
MBMarta Bes
Marta Bes
MBMaria Buti
Maria Buti
Hepatitis B virus (HBV) biomarkers have been used for a better categorization of patients, even though the lack of simple algorithms and the impact of genotypes limit their application. Our aim was to assess the usefulness of noninvasive markers for the identification of HBV inactive carriers (ICs) in a single-point evaluation and to design a predictive model for their identification.

10 April 2019 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
CSClive R. Seed
Clive R. Seed
JAJean‐Pierre Allain
Jean‐Pierre Allain
MLMiquel Lozano
Miquel Lozano
SLSyria Laperche
Syria Laperche
PGPierre Gallian
Pierre Gallian
MSMichael Schmidt
Michael Schmidt

6 September 2022 in Viruses
Verified
Journal Article
Open access
PDF file
MPMaria Piron
Maria Piron
Fernando SalvadorFernando Salvador
Fernando Salvador
ECEstrella Caballero
Estrella Caballero
AMAdrian-Sanchez Montalva
Adrian-Sanchez Montalva
MBMarta Bes
Marta Bes
SSSILVIA SAULEDA
SILVIA SAULEDA
Human T-cell lymphotropic virus type 1 and 2 (HTLV-1/2) screening is not mandatory in Spanish blood banks. In Catalonia, selective screening was introduced in 2008, followed by universal screening in 2011. We present herein a 10-year experience of HTLV testing in blood donors. HTLV-1/2 selective screening was performed using Ortho-Clinical Diagnostics HTLV-I/HTLV-II Ab-Capture ELISA between February 2008 and May 2009, then Abbott Prism HTLV-I/ HTLV-II assay until December 2010. Abbott Architect rHTLV-I/II assay was then used for HTLV-1/2 universal screening in pooled samples. INNO-LIA HTLV I/II Score (Fujirebio) and in-house HTLV-1/2 proviral DNA real-time PCR were used in reactive samples. Follow-up was offered to confirm HTLV-1/2 donors in Vall d’Hebron Hospital. Between 2008 and 2017, 51 blood donors were confirmed HTLV positive (46 HTLV-1, 4 HTLV-2 and 1 HTLV) out of 2,114,891 blood donations (1 in 41,468). Sixty-nine percent were female, median age was 40 years and most were born in Latin America (69%), followed by Europe (25%), Africa (4%) and Asia (2%). Screening of relatives and partners identified 12 additional HTLV-1 cases. Lookback studies did not show any HTLV-1/2 transmission. HTLV infections found in blood donors mirror epidemiological changes in the population of Spain. Consequently, HTLV should be considered a potential risk for recipients and calls for the design of optimal strategies to ensure transfusion safety.